TherapeuticsMD
TXMD
131 hedge funds and large institutions have $44M invested in TherapeuticsMD in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 51 reducing their positions, and 33 closing their positions.
111% more call options, than puts
Call options by funds: $438K | Put options by funds: $208K
0.04% less ownership
Funds ownership: 0.63% → 0.58% (-0.04%)
12% less funds holding
Funds holding: 149 → 131 (-18)
39% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 51
48% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 33
55% less capital invested
Capital invested by funds: $98.2M → $44M (-$54.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$730K |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$572K |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
+$537K |
| 4 |
D.E. Shaw & Co
New York
|
+$527K |
| 5 |
AMG
Asset Management Group
Stamford,
Connecticut
|
+$429K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$1.83M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.13M |
| 3 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$755K |
| 4 |
Swiss National Bank
Zurich,
Switzerland
|
-$621K |
| 5 |
Millennium Management
New York
|
-$494K |
TXMD Hedge Fund Activity: Q4 2021 in Review
131 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q4 2021, worth a combined $44M — down 55% from $98.2M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of TXMD and 17 opened new positions — a net loss of 16 holders — while 51 trimmed existing stakes and 31 added.
The largest buyer was Vanguard Group, adding an estimated $730K. The largest seller was Sanders Morris Harris, cutting an estimated $1.83M.
- 131 institutional investors held TherapeuticsMD (TXMD) as of Q4 2021, down from 149 in Q3 2021.
- Funds reported $44M of TherapeuticsMD stock for Q4 2021, down 55% quarter-over-quarter.
- 17 funds opened new TherapeuticsMD positions in Q4 2021 and 33 closed out, a net change of -16 holders.
- The largest TherapeuticsMD buyer in Q4 2021 was Vanguard Group, an estimated $730K added.
- The largest TherapeuticsMD seller in Q4 2021 was Sanders Morris Harris, an estimated $1.83M sold.
Based on aggregated 13F filings for Q4 2021.